MedTrace Logo

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

NCT00636935 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-06-27

No results posted yet for this study

Summary

To explore the effects of corticosteroid therapy on pulmonary fibrosis and potentially pneumothorax in patients with mild PCP (pO2 \>70mmHg) combined with the standard of care treatment of antibiotic therapy.

Conditions

  • Pneumocystis Carinii Pneumonia

Interventions

DRUG

Antibiotics only

Antibiotic only for treatment for mild (pO2 \> 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.

DRUG

Antibiotics + Corticosteroids

Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).

DRUG

Corticosteroids + antibiotics

Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Principal Investigators

  • Afsoon Roberts, M.D. · George Washington University Medical Faculty Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636935 on ClinicalTrials.gov